Trial Success Buzz: Recent discussions on social media have been dominated by Alumis Inc.'s positive Phase 3 trial results for their psoriasis drug, envudeucitinib. Many are highlighting the impressive skin clearance rates, fueling a surge in stock interest. The news has sparked excitement among biotech investors.
Investor Confidence: Alongside the trial data, chatter on social media also focuses on insider buying and a recent $345.1 million public offering. Some are noting price targets significantly above current levels, suggesting optimism about future catalysts. This has kept the conversation lively and forward-looking.
Note: This discussion summary was generated from an AI condensation of post data.
Alumis Inc. Insider Trading Activity
Alumis Inc. insiders have traded $ALMS stock on the open market 32 times in the past 6 months. Of those trades, 32 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ALMS stock by insiders over the last 6 months:
- JAMES B. TANANBAUM has made 6 purchases buying 919,638 shares for an estimated $10,094,713 and 0 sales.
- CAPITAL MANAGEMENT VI LLC FORESITE has made 6 purchases buying 919,638 shares for an estimated $10,094,713 and 0 sales.
- LABS, LLC FORESITE has made 6 purchases buying 919,638 shares for an estimated $10,094,713 and 0 sales.
- SRINIVAS AKKARAJU has made 14 purchases buying 1,265,253 shares for an estimated $9,069,492 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Alumis Inc. Hedge Fund Activity
We have seen 66 institutional investors add shares of Alumis Inc. stock to their portfolio, and 45 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WOODLINE PARTNERS LP added 1,558,660 shares (+809.7%) to their portfolio in Q3 2025, for an estimated $6,219,053
- MADISON AVENUE PARTNERS, LP removed 1,424,492 shares (-77.3%) from their portfolio in Q3 2025, for an estimated $5,683,723
- TANG CAPITAL MANAGEMENT LLC removed 829,788 shares (-41.6%) from their portfolio in Q3 2025, for an estimated $3,310,854
- VELAN CAPITAL INVESTMENT MANAGEMENT LP removed 674,163 shares (-41.6%) from their portfolio in Q3 2025, for an estimated $2,689,910
- VANGUARD GROUP INC added 625,404 shares (+18.4%) to their portfolio in Q3 2025, for an estimated $2,495,361
- CANTOR FITZGERALD, L. P. removed 559,201 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,231,211
- UBS GROUP AG removed 444,880 shares (-36.8%) from their portfolio in Q3 2025, for an estimated $1,775,071
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Alumis Inc. Analyst Ratings
Wall Street analysts have issued reports on $ALMS in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 01/09/2026
- Wells Fargo issued a "Overweight" rating on 01/06/2026
- Morgan Stanley issued a "Overweight" rating on 08/15/2025
To track analyst ratings and price targets for Alumis Inc., check out Quiver Quantitative's $ALMS forecast page.
Alumis Inc. Price Targets
Multiple analysts have issued price targets for $ALMS recently. We have seen 6 analysts offer price targets for $ALMS in the last 6 months, with a median target of $32.5.
Here are some recent targets:
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $40.0 on 01/09/2026
- Yatin Suneja from Guggenheim set a target price of $32.0 on 01/07/2026
- Terence Flynn from Morgan Stanley set a target price of $33.0 on 01/07/2026
- Thomas Smith from Leerink Partners set a target price of $32.0 on 01/07/2026
- Derek Archila from Wells Fargo set a target price of $39.0 on 01/06/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
